DK0666912T3 - Modificerede ciliære neurotiske faktorer - Google Patents

Modificerede ciliære neurotiske faktorer

Info

Publication number
DK0666912T3
DK0666912T3 DK93923333.4T DK93923333T DK0666912T3 DK 0666912 T3 DK0666912 T3 DK 0666912T3 DK 93923333 T DK93923333 T DK 93923333T DK 0666912 T3 DK0666912 T3 DK 0666912T3
Authority
DK
Denmark
Prior art keywords
factors
modified ciliary
neurotic
modified
ciliary neurotic
Prior art date
Application number
DK93923333.4T
Other languages
Danish (da)
English (en)
Inventor
Nikos Panayotatos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK0666912T3 publication Critical patent/DK0666912T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/12Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DK93923333.4T 1992-10-09 1993-10-08 Modificerede ciliære neurotiske faktorer DK0666912T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/959,284 US5349056A (en) 1992-10-09 1992-10-09 Modified ciliary neurotrophic factors

Publications (1)

Publication Number Publication Date
DK0666912T3 true DK0666912T3 (da) 1997-09-29

Family

ID=25501875

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93923333.4T DK0666912T3 (da) 1992-10-09 1993-10-08 Modificerede ciliære neurotiske faktorer

Country Status (14)

Country Link
US (5) US5349056A (ja)
EP (1) EP0666912B1 (ja)
JP (1) JP2702811B2 (ja)
AT (1) ATE151460T1 (ja)
AU (1) AU667996B2 (ja)
CA (1) CA2132954C (ja)
DE (1) DE69309702T2 (ja)
DK (1) DK0666912T3 (ja)
ES (1) ES2099981T3 (ja)
GR (1) GR3024039T3 (ja)
HK (1) HK1007767A1 (ja)
IL (1) IL107213A0 (ja)
WO (1) WO1994009134A2 (ja)
ZA (1) ZA937482B (ja)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141856A (en) * 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
ATE163006T1 (de) * 1993-06-01 1998-02-15 Ono Pharmaceutical Co Pentansäurederivate
EP0749980A4 (en) * 1993-12-29 1999-09-29 Sumitomo Pharma NEW CELLAR FACTOR FROM HUMAN
AU7204996A (en) * 1995-10-02 1997-04-28 Cytotherapeutics, Inc. Method for treating amyotrophic lateral sclerosis
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
IT1284867B1 (it) * 1996-07-10 1998-05-22 Angeletti P Ist Richerche Bio Varianti del fattore neurotrofico ciliare umano (hcntf) con uno spettro di azione differente dalla molecola di tipo selvatico
CN1233963A (zh) 1996-09-13 1999-11-03 有限会社最先端医学研究所 神经营养因子的眼科用组合物、视神经机能障碍治疗药和视神经机能障碍治疗方法
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
PL364931A1 (en) * 1999-08-13 2004-12-27 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor, method of making and methods of use thereof
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
WO2002064021A2 (en) * 2001-02-12 2002-08-22 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of ciliary neurotrophic factor activity
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
JP2005516001A (ja) 2001-12-05 2005-06-02 ベイラー カレッジ オブ メディスン 交感神経活動状態の調節による骨形成の制御のための方法及び組成物
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
AU2003275846A1 (en) * 2002-10-24 2004-05-13 The University Of British Columbia Methods for neuroprotection
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Jx日鉱日石エネルギー株式会社 潤滑油組成物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2864810A1 (en) 2003-04-18 2004-11-04 Biogen Idec Ma, Inc. Polymer-conjugated glycosylated neublastin
CA2753318A1 (en) 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
WO2005014641A2 (en) * 2003-07-09 2005-02-17 Xencor, Inc. Ciliary neurotrophic factor variants
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EP2238983B1 (en) * 2004-08-19 2014-07-23 Biogen Idec MA Inc. Neublastin variants
NZ553420A (en) 2004-08-19 2010-02-26 Biogen Idec Inc Refolding transforming growth factor beta family proteins
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US20060178301A1 (en) * 2005-02-04 2006-08-10 Mathias Jurs Albumin-fused ciliary neurotrophic factor
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
JPWO2007024004A1 (ja) 2005-08-24 2009-03-05 萬有製薬株式会社 フェニルピリドン誘導体
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および/または抗肥満症剤の組み合わせ
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
US8026377B2 (en) 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
EP1953165B1 (en) 2005-11-10 2012-02-01 Msd K.K. Aza-substituted spiro derivative
RU2008131939A (ru) * 2006-02-02 2010-02-10 Ринат Ньюросайенс Корп. (Us) Способы лечения нежелательной потери веса или нарушений приема пищи агонистами trkb
CA2637707A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2450065T3 (es) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
CA2664358A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diarylketimine derivative
AU2007337809A1 (en) * 2006-12-20 2008-07-03 Rinat Neuroscience Corporation TrkB agonists for treating autoimmune disorders
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
US8329655B2 (en) * 2007-05-01 2012-12-11 Biogen Idec Ma Inc. Methods for increasing vascularization
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US20100297081A1 (en) * 2007-12-18 2010-11-25 Huang Yanshan Pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
WO2009110510A1 (ja) 2008-03-06 2009-09-11 萬有製薬株式会社 アルキルアミノピリジン誘導体
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Msd株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Msd株式会社 5員−5員又は5員−6員縮環シクロアルキルアミン誘導体
CN102264228A (zh) 2008-10-22 2011-11-30 默沙东公司 用于抗糖尿病药的新的环状苯并咪唑衍生物
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
EP3823674A4 (en) 2018-07-18 2022-12-28 Manzanita Pharmaceuticals, Inc. CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF
CN113302189A (zh) 2018-11-20 2021-08-24 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4997929A (en) * 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
EP0446931A1 (en) * 1990-03-14 1991-09-18 FIDIA S.p.A. Human ciliary neuronotrophic factor, DNA sequence encoding the factor, and production of the factor by recombinant technology
EP0596034A4 (en) * 1991-07-23 1995-05-24 Syntex Inc CLEANING CILIARY NEUROTROPHIC FACTOR (CNTF) AND C-TERMINAL SHORTENED CNTF AND METHOD FOR TREATING DAMAGE TO PERIPHERAL NERVES.
US5593857A (en) * 1991-08-23 1997-01-14 Scios Inc. Production of homogeneous truncated CNTF
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors

Also Published As

Publication number Publication date
US20030092129A1 (en) 2003-05-15
EP0666912A1 (en) 1995-08-16
AU667996B2 (en) 1996-04-18
ES2099981T3 (es) 1997-06-01
GR3024039T3 (en) 1997-10-31
WO1994009134A2 (en) 1994-04-28
DE69309702T2 (de) 1997-10-30
WO1994009134A3 (en) 1994-05-26
ZA937482B (en) 1994-04-26
US20030220484A1 (en) 2003-11-27
AU5326094A (en) 1994-05-09
JP2702811B2 (ja) 1998-01-26
ATE151460T1 (de) 1997-04-15
IL107213A0 (en) 1994-01-25
HK1007767A1 (en) 1999-04-23
CA2132954A1 (en) 1994-04-28
US6440702B1 (en) 2002-08-27
CA2132954C (en) 2000-01-18
JPH07506005A (ja) 1995-07-06
US5846935A (en) 1998-12-08
EP0666912B1 (en) 1997-04-09
DE69309702D1 (de) 1997-05-15
US5349056A (en) 1994-09-20

Similar Documents

Publication Publication Date Title
DK0666912T3 (da) Modificerede ciliære neurotiske faktorer
DE69431285D1 (de) Herstellungsmethode von markierten genen; transcripten und proteinen
DE69028675T2 (de) Wahrnehmungsgebundene Kodierung von Audiosignalen
DE69435262D1 (de) Herstellungsverfahren von Elektroden
NO173533C (no) Perlemorskimrende sjampo og fremgangsmaate for fremstilling av denne
ES546654A0 (es) Metodo de produccion de factor viii:c humano
IT9020763A0 (it) metodo per formare
ATE112802T1 (de) Herstellung von funktionellen menschlichen urokinasepolypeptiden.
DE68929060D1 (de) Synthese von 1,2-Dioxetanen und Zwischenprodukte dafür
DE68918245T2 (de) Verfahren zum Herstellen von Schmuckstücken.
DE69020009T2 (de) Verfahren zum Herstellen von Verbindungselektroden.
ATE71658T1 (de) Verfahren zur herstellung von humanlysozym.
ES2123582T3 (es) Proteina con capacidad de formacion de huesos y procedimiento para su produccion.
DK398987D0 (da) Fremgangsmaade til fremstilling af blodprotein
ES2135477T3 (es) Proceso de produccion de (s)-3-amino-1-pirrolidinas sustituidas.
DE68910395T2 (de) Verfahren zur Herstellen von Kolbenringen.
DE69025446T2 (de) Verfahren zur Herstellung von Tonern
KR880005263A (ko) 단백질의 신규제법
BR8506371A (pt) Processo de producao de polissacarideos por fermentacao e emulsoes de oleo-em-agua
ATE96177T1 (de) Fibrinspezifischer antikoerper, verfahren zu seiner herstellung und seine verwendung.
DE69318270D1 (de) Verfahren zum Herstellen von Scharnieren
GR900100615A (el) Νεοι υποκατεστημενοι ετεροκυκλικοι δακτυλιοι πεντανιου,παραγωγη και χρησις αυτων.
ATE210605T1 (de) Verwendung von sulfonamiden zur kontrolle von biobewuchs
DE3670224D1 (de) Verfahren zur herstellung von scharnierstiften und damit erzeugte scharniere.
FR2619839B1 (fr) Pont haubane et son procede de construction